Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
SLDB
SLDB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest SLDB ETF News Today | Earnings, Events & Price Alerts
SLDB News
Solid Biosciences Receives Positive FDA Feedback
Feb 09 2026
NASDAQ.COM
Solid Biosciences Aligns with FDA on Late-Stage Trial for DMD Treatment
Feb 09 2026
seekingalpha
Solid Biosciences Aligns with FDA to Advance SGT-003 for Duchenne
Feb 09 2026
Newsfilter
Solid Biosciences CEO to Present at Biotech Summit 2026
Feb 06 2026
Newsfilter
Sarepta Shares Rise as 3-Year Elevidys Study Results Offer Promise.
Jan 26 2026
Barron's
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial
Jan 14 2026
seekingalpha
Solid Biosciences (SLDB) Receives FDA Orphan Drug Designation for SGT-212, Phase 1b Trial Initiated
Jan 13 2026
NASDAQ.COM
Solid Biosciences Receives FDA Fast Track and Orphan Drug Designations for SGT-212, Initiates Phase 1b Trial
Jan 12 2026
Globenewswire
Solid Biosciences Grants 7,000 RSUs to New Employee as Inducement
Jan 05 2026
Globenewswire
Biotech Sector Sustains After-Hours Trading Gains
Dec 18 2025
NASDAQ.COM
Solid Biosciences Advances Duchenne Screening with RUSP Inclusion
Dec 16 2025
Globenewswire
Solid Biosciences Advocates for Duchenne Screening Inclusion in RUSP
Dec 16 2025
Newsfilter
Solid Biosciences Presents New Cardiac Gene Therapy Data at CVCT Forum
Dec 08 2025
Globenewswire
Solid Biosciences: Analyst Optimistic About Company's Competitive Edge in DMD Gene Therapy
Dec 04 2025
Benzinga
AutoZone Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Dec 04 2025
Benzinga
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212, Initiates Clinical Trial
Dec 01 2025
Newsfilter
Show More News
